Evidence map›Paper›PMID 38271627›Full record

ArticleBiology of reproduction2024

High-throughput mRNA-seq atlas of human placenta shows vast transcriptome remodeling from first to third trimester†.

Tania L Gonzalez, Sahar Wertheimer, Amy E Flowers, Yizhou Wang, Chintda Santiskulvong, Ekaterina L Clark, Caroline A Jefferies, Kate Lawrenson, Jessica L Chan, Nikhil V Joshi and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of reproduction, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Tania L GonzalezDepartment of Obstetrics and Gynecology, Center for Reproductive Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sahar WertheimerDepartment of Obstetrics and Gynecology, Center for Reproductive Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Amy E FlowersDepartment of Obstetrics and Gynecology, Center for Reproductive Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Yizhou WangDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Chintda SantiskulvongCS Cancer Applied Genomics Shared Resource, CS Cancer, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ekaterina L ClarkDepartment of Obstetrics and Gynecology, Center for Reproductive Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Caroline A JefferiesDivision of Rheumatology, Department of Medicine, Kao Autoimmune Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Kate LawrensonDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jessica L ChanDepartment of Obstetrics and Gynecology, Center for Reproductive Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Nikhil V JoshiDepartment of Obstetrics and Gynecology, Center for Reproductive Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Yazhen ZhuDavid Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Hsian-Rong TsengCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
S Ananth KarumanchiDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
John Williams IiiDavid Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Margareta D PisarskaDepartment of Obstetrics and Gynecology, Center for Reproductive Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Cedars-Sinai Medical Center · USCalifornia NanoSystems Institute · USGynecologic Oncology Group · US

Funding

Non-Invasive Prenatal Diagnostics Based on Circulating TrophoblastsU01EB026421 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PISARSKA, MARGARETA, TSENG, HSIAN-RONG · 2019 to 2023
$4.0M
Training Program in Endocrinology, Diabetes, and MetabolismT32DK007770 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI MELMED, SHLOMO · 1999 to 2022
$3.4M
Sex and gender differences in lupus - intersection between immunometabolism, epigenetic remodeling and cardiac involvementR01AI164504 · NIAID · CEDARS-SINAI MEDICAL CENTER · PI JEFFERIES, CAROLINE · 2021 to 2024
$2.3M
The impact of sex and gender on disease progression, from developmental originsR01AI154535 · NIAID · CEDARS-SINAI MEDICAL CENTER · PI PISARSKA, MARGARETA · 2020 to 2024
$2.3M
Placental Organoids to Model PreeclampsiaR01HL167268 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI S. Ananth Karumanchi · 2023 to 2026
$1.7M
Noncoding RNA regulation of the human placental transcriptome among the sexesR01HD091773 · NICHD · CEDARS-SINAI MEDICAL CENTER · PI PISARSKA, MARGARETA · 2017 to 2018
$900k
Eunice Kennedy Shriver National Institute of Child Health and Human Development R01HD091773National Heart Lung and Blood Institute R01HL167268National Institute of Allergy and Infectious Disease R01AI154535NHLBI NIH HHS R01 HL167268NIAID NIH HHS R01 AI154535NIAID NIH HHS R01 AI164504NIBIB NIH HHS U01 EB026421NIBIB NIH HHS U01EB026421NICHD NIH HHS R01 HD091773NIDDK NIH HHS T32 DK007770NIH HHSTraining Program in Endocrinology, Diabetes, and Metabolism T32DK007770
6 · The paper itself

Abstract

The placenta, composed of chorionic villi, changes dramatically across gestation. Understanding differences in ongoing pregnancies are essential to identify the role of chorionic villi at specific times in gestation and develop biomarkers and prognostic indicators of maternal-fetal health. The normative mRNA profile is established using next-generation sequencing of 124 first trimester and 43 third trimester human placentas from ongoing healthy pregnancies. Stably expressed genes (SEGs) not different between trimesters and with low variability are identified. Differential expression analysis of first versus third trimester adjusted for fetal sex is performed, followed by a subanalysis with 23 matched pregnancies to control for subject variability using the same genetic and environmental background. Placenta expresses 14,979 polyadenylated genes above sequencing noise (transcripts per million > 0.66), with 10.7% SEGs across gestation. Differentially expressed genes (DEGs) account for 86.7% of genes in the full cohort [false discovery rate (FDR) < 0.05]. Fold changes highly correlate between the full cohort and subanalysis (Pearson = 0.98). At stricter thresholds (FDR < 0.001, fold change > 1.5), there remains 50.1% DEGs (3353 upregulated in first and 4155 upregulated in third trimester). This is the largest mRNA atlas of healthy human placenta across gestation, controlling for genetic and environmental factors, demonstrating substantial changes from first to third trimester in chorionic villi. Specific differences and SEGs may be used to understand the specific role of the chorionic villi throughout gestation and develop first trimester biomarkers of placental health that transpire across gestation, which can be used for future development of biomarkers for maternal-fetal health.

Indexed as

PlacentaPregnancy Trimester, FirstPregnancy Trimester, ThirdRNA, MessengerTranscriptomeAdultFemaleHigh-Throughput Nucleotide SequencingHumansPregnancyRNA, Messengerchorionic villigestational differenceshuman transcriptomemRNAplacentapregnancy

Identifiers

PMID38271627
PMCPMC11094392
OpenAlexW4391214803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.